The medicine of the future is personalized, precise and holistic. One of the most promising approaches in this new era is apheresis therapy, which specifically removes unwanted substances from the blood to treat inflammation, lipid disorders and even chronic infections.
In the following, we take a look at the latest scientific findings that shed light on the potential of apheresis in various medical fields.
Lipoprotein apheresis (LA) has established itself as a highly effective therapy for the treatment of familial hypercholesterolemia and lipoprotein(a) hyperlipidemia.
Despite its invasive nature, it shows
"Can apheresis do more than just lower cholesterol?"
In fact, studies indicate that the effectiveness of LA goes beyond pure lipid reduction. It also removes proinflammatory and proatherogenic factors, leading to a more comprehensive cardiovascular risk reduction.
Plastic pollution is no longer a purely ecological problem. Microplastics have become a serious threat to food systems and human health.
"How much does microplastic affect our blood, our cells - and ultimately our well-being?"
Studies show:
The findings on nanoplastics (NPs) are particularly alarming - they indicate chronic toxicity affecting the liver, heart and nervous system.
Lyme borreliosis, caused by Borrelia burgdorferi, is a complex bacterial infection that causes a variety of symptoms. The latest research indicates a close link between lipid metabolism and the course of the disease.
Research results show:
These findings lead to an exciting hypothesis:
Apheresis could help to influenceinflammatory processes and bacterial persistence through lipid reduction. Initial pilot trials support this innovative approach - further research is underway.
Many patients struggle with persistent symptoms after a SARS-CoV-2 infection - known as post-COVID or long-COVID. These include:
This symptomatology is very similar to chronic fatigue syndrome (CFS).
"What if the solution to fatigue lies in the blood itself?"
Current studies show increased autoantibodies against neurotransmitter receptors in Long COVID and CFS patients.
Extracorporeal apheresis offers a new approach here:
Double filtration plasmapheresis (DFPP) is an advanced blood purification procedure associated with INUSpheresis® technology.
A recent study investigated which micro- and nanoparticles remain in the eluate after treatment.
"What remains after the blood has been purified?"
Field emission scanning electron microscopy (FE-SEM-EDX) was used to identify particles that:
These findings emphasize that DFPP technology can be valuable not only therapeutically but also diagnostically.
Chronic inflammation is considered to be the silent driver of numerous diseases - from autoimmune diseases to neurodegenerative processes.
"Can we stop inflammation before it becomes a disease?"
This is where INUSpheresis® therapy comes in:
Typical indications for INUSpheresis®:
The studies presented here clearly show that apheresis is more than just a classic detoxification:
It is a precise, science-based approach that harmonizes metabolism, immune system and cellular health.
With procedures such as INUSpheresis®, medicine is becoming increasingly individualized - with the aim of treating diseases holistically before they become chronic.
"Precision medicine begins where therapy is tailored to the biochemistry of the individual."